Open AccessCOVID‐19: vaccine’s progress
Author(s) -
Brüssow Harald
Publication year - 2021
Publication title -
microbial biotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.287
H-Index - 74
ISSN - 1751-7915
DOI - 10.1111/1751-7915.13818
Subject(s) - vaccination , covid-19 , virology , pandemic , mass vaccination , medicine , attenuated vaccine , immunology , disease , biology , infectious disease (medical specialty) , outbreak , biochemistry , pathology , virulence , gene
Summary Under the pressure of the COVID‐19 pandemic, vaccines were developed and rolled out into mass vaccination campaigns at incredible speed. What normally takes a decade was worked out within a year. Vaccines were produced along many different platforms ranging from inactivated whole virus vaccines over adenovirus‐vectored vaccines, recombinant protein vaccines and nanoparticles to mRNA vaccines. Several vaccines went through preclinical testing and completed successful phase 1 to phase 3 clinical trials. The first evaluations of national vaccination campaigns document astonishing high levels of protection against disease. The present article summarizes the published reports leading to these striking achievements with vaccines based on different concepts.